Navigation Links
Myeloma in Biological Technology

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

... in relapsed or relapsed/refractory multiple myeloma patients previously treated with bortezomib ... of Bortezomib and Dexamethasone in Multiple myeloma Patients Previously Treated with Bortezomib", ... overall survival and safety. About Multiple myeloma Multiple myeloma, a cancer of the plasma ...

Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

... of carfilzomib for the treatment of multiple myeloma at the 14th Congress of the European Hematology ... and solid tumors. Relapsed Multiple myeloma Patients Achieve Responses with Single-Agent ... of single-agent carfilzomib in relapsed multiple myeloma patients. Patients in the study have relapsed ...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... (B) versus B alone in previously treated multiple myeloma (MM) (Abstract 8591) General Poster Session, ... for the treatment of patients with multiple myeloma who have not previously received VELCADE and have ... injury In the randomized multiple myeloma study, 25 patients (8%) in the VELCADE for ...

Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting

... of Carfilzomib in Relapsed/Refractory Multiple myeloma and Advanced Solid Tumors Featured in Oral ... from clinical trials of carfilzomib in multiple myeloma and advanced solid tumors will be presented at ... approval study in relapsed/refractory multiple myeloma and Phase 2 clinical studies in relapsed ...

Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results

... in mice for SNS-01, the Company's multiple myeloma drug candidate. Management delivered the ... application for SNS-01, the Company's multiple myeloma drug candidate, before the end of calendar year ... programs, specifically the Company's multiple myeloma research program, which was partially offset by a ...

Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results

... in mice for SNS-01, the Company's multiple myeloma drug candidate. Senesco's data was ... in Vivo". Senesco's preclinical multiple myeloma data was presented at the 20th EORTC-NCI-AACR ... programs, specifically the Company's multiple myeloma research program, which was partially offset by a ...

International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"

... for the diagnosis and monitoring of multiple myeloma (MM) and related disorders. Immunoglobulin free ... in the diagnosis and treatment of multiple myeloma and other plasma cell disorders. Not only does ... worldwide." Eric Low, Chief Executive of myeloma UK, the only organisation dealing exclusively ...

Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology

... Sundar Jagannath, M.D., Chief of the Multiple myeloma Program, Bone Marrow and Blood Stem Cell ... myeloma patients during the Novel Therapies for myeloma and Related Disorders oral session at the 50th ... by Proteolix in collaboration with the Multiple myeloma Research Consortium (MMRC). Activity in ...

EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma

... Phase 1 study of ENMD-2076 in refractory multiple myeloma patients. The study will be conducted at the ... orally once a day in patients with multiple myeloma who are refractory to other drug therapy. The ... of ENMD-2076 alone and in combination in multiple myeloma were presented by Dr. Farag earlier this week at ...

Proteolix Raises $79 Million in Series C Financing

... in clinical and preclinical studies in multiple myeloma and a variety of other tumor types. Proceeds from ... carfilzomib to registration studies for multiple myeloma while continuing to cultivate select early-stage ... evaluating the compound's activity among multiple myeloma patients who have failed or relapsed following ...

Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results

... injected subcutaneously with human multiple myeloma cancer cells to form myeloma tumors in their flanks. Treated mice were ... positive preclinical results in our multiple myeloma studies and pancreatic islet cell research. ...

JCI table of contents: April 22, 2008

... cyclin D2 in cells from individuals with multiple myeloma and myeloma cell lines, causing the cells to stop growing and to die. The chemical also prevented myeloma cell lines from growing when transplanted into ...

Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR

... our first generation Hsp90 inhibitor, in multiple myeloma and in breast cancer, is Kosan's highest ... acute myelogenous leukemia (AML), multiple myeloma and colon cancer models. Most notably, KOS-2484 ... Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin ...

Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales

... for the treatment of patients with multiple myeloma who have received at least one prior therapy. ... rest period in 1163 patients with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were ... of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated ...

Proteolix's Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma

... designation encompasses all subsets of multiple myeloma and Waldenstrom's macroglobulinemia. "I am very ... Institute (2004), the U.S. prevalence of multiple myeloma was 53,712 patients. The Orphan Drug Act provides ... indication. About Multiple Myeloma Multiple myeloma is cancer of the plasma cell. It begins in the ...

Kosan Announces Senior Management Changes and Clinical Portfolio Priorities

... Hsp90 inhibitor tanespimycin, in multiple myeloma and in metastatic breast cancer, and its lead ... to initiate a supporting trial in multiple myeloma in early 2009. -- Kosan plans to advance ... use of our resources." Tanespimycin in myeloma Evaluation (TIME) Registration Program on Track ...

Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook

... in the TIME registration program in multiple myeloma and preparation for the KOS-1584 Phase 2 clinical ... of the tanespimycin TIME program in multiple myeloma and the tanespimycin metastatic breast cancer ... bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin ...

Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress

... in multiple myeloma - ROCKVILLE, Md., Feb. 25 ... Data from HGS- ETR1 Phase 2 Multiple myeloma Trial Expected by 3rd Quarter In December 2007, ... with Velcade (bortezomib) in advanced multiple myeloma and expects to have data available in the third ...

Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results

... injected subcutaneously with human multiple myeloma cancer cells to form myeloma tumors in their flanks. Treated mice were ... encapsulation vehicles in preclinical multiple myeloma cancer models, to identify contract manufacturing ...

Millennium Over-Delivers on 2007 Goals and Financial Guidance

... treatment for relapsed multiple myeloma and mantle cell lymphoma. Sales increased ... based combinations in newly diagnosed multiple myeloma were featured at the 2007 Annual Meeting of ... standard of care regimens in the multiple myeloma transplant and non-transplant settings. Data ...

Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results

... for VELCADE expansion into front-line multiple myeloma - - MLN0002 core bridging studies fully enrolled, ... expected launch in front-line multiple myeloma is the next catalyst for VELCADE. Our late-stage ... Drive timely approval in newly diagnosed multiple myeloma and execute a successful commercial launch, ...

Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection

... is the market leader in the relapsed multiple myeloma setting with a pending approval in the front-line ... of the U.S. About Multiple Myeloma Multiple myeloma is the second most common hematologic malignancy ... U.S., more than 55,000 individuals have multiple myeloma and approximately 20,000 new cases are diagnosed ...

Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales

... Phase III VISTA trial in newly diagnosed multiple myeloma stopped early due to positive interim analysis; ... diagnosed multiple myeloma -- -- VELCADE label broadened by FDA providing ... as leading multiple myeloma therapy -- CAMBRIDGE, Mass., Nov. 1 ...

The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma

... Conn., Aug. 15 /PRNewswire/ -- The Multiple myeloma Research Consortium (MMRC) and Proteolix, Inc. ... class of drugs for the treatment of multiple myeloma and we are proud to work with Proteolix ... to bring better, more effective treatments to myeloma patients as quickly as possible." The trial will ...

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

... we can concentrate our efforts on the disease targets of both multiple myeloma and metastatic colon cancer where, unlike the non-small cell lung cancer ... daily until progression. Recently, positive Phase 2 data for multiple myeloma and metastatic colon cancer were presented at ASH and ASCO meeting, ...

Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team

... lead anti-cancer proteasome inhibitor for the treatment of multiple myeloma and other cancers, through late-stage clinical development. In addition, ... Phase 2 clinical studies to evaluate its safety and efficacy in multiple myeloma and other malignancies. Proteolix is also developing a pipeline of novel ...

Senesco's Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'

... will be presenting her findings related to Senesco's preclinical multiple myeloma data at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer ... the study entitled "Therapeutic intervention in a murine model of multiple myeloma with PEI nanocomplexes bearing an eIF5A siRNA and eIF5AK50R pDNA resulted ...

Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments

... expected in August 2008 - - Initial data from Phase 2 HGS-ETR1 multiple myeloma study expected in third quarter 2008 - ... Phase 3 trials. Oncology Products: Initial Data from HGS-ETR1 Multiple myeloma Trial Expected Third Quarter 2008; Completion of Randomization in HGS-ETR1 ...

Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System

... and plasmid delivered with "in vivo-jetPEI" against subcutaneous multiple myeloma tumors in immunodeficient mice. "This supply agreement will help Senesco ... are proud that Senesco has chosen our delivery system targeting multiple myeloma and that we have an agreement to supply the company according to this ...

Oncolytics Biotech Inc. Announces 2008 First Quarter Results

... of the Tom Baker Cancer Centre, Calgary, entitled "Targeting Multiple myeloma with Oncolytic Viral Therapy" was presented at the AACR Annual Meeting. ... for multiple myeloma. The results demonstrated that up to 70% of multiple myeloma cell lines tested showed reovirus sensitivity and reovirus induced cancer ...

Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting

... of the Tom Baker Cancer Centre, Calgary, entitled "Targeting Multiple myeloma with Oncolytic Viral Therapy" was presented today at the American ... for multiple myeloma. The results demonstrated that up to 70% of multiple myeloma cell lines tested showed reovirus sensitivity and reovirus induced cell ...

Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs

... advancement of its lead clinical programs, tanespimycin in multiple myeloma and in metastatic breast cancer, and epothilone KOS-1584 in non-small lung ... in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied ...

Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting

... April 12-16, 2008. The first abstract, entitled "Targeting Multiple myeloma with Oncolytic Viral Therapy" covers preclinical work using reovirus as a ... for multiple myeloma. The results demonstrated that up to 70% of multiple myeloma cell lines tested showed reovirus sensitivity and reovirus induced cell ...

Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies

... today the results of preclinical animal studies focused on multiple myeloma that were conducted concurrently at Mayo Clinic and the University of ... immunodeficiency) mice were injected subcutaneously with human multiple myeloma cancer cells to form myeloma tumors in their flanks. Treated mice were ...

Kosan Biosciences to Host Research & Development Day on October 31, 2007

... of Hematologic Neoplasia, Director of the Jerome Lipper Multiple myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine at ... in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied ...

Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing

... with the private placement. Senesco primarily intends to utilize the net proceeds of these transactions to further advance its multiple myeloma research and development program with the goal of initiating a Phase I clinical trial. "We are excited by the potential of SNS-101 as a ...

Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)

... including osteoporosis, bone metastases and their consequences, cancer treatment-induced bone loss due to hormone ablative therapy, multiple myeloma and bone erosions in rheumatoid arthritis. Denosumab is the first late-stage investigational therapy that specifically inhibits RANK Ligand, an ...

Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing

... Senesco primarily intends to utilize the proceeds of this private placement as an initial step to help advance its research in multiple myeloma with the goal of initiating a Phase I clinical trial. "We are pleased to have raised this additional capital," commented Joel Brooks, Chief ...

Senesco Technologies, Inc. Announces the Appointment of Dr. Harlan W. Waksal, M.D. as Chairman of the Board of Directors and the Addition of Mr. Warren J. Isabelle, CFA to its Board of Directors

... "With Senesco's groundbreaking technologies, its research focus on human health and its plans to move diligently into clinical trials with a Multiple myeloma cancer project, the recent addition of Dr. Waksal to Senesco's Board gave us a unique opportunity to ask him to take on these new responsibilities as ...

Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy

... SNT ) announced today that Richard Dondero, Vice President of Research and Development, will be presenting pre-clinical data from Senesco's multiple myeloma studies at the 12th Annual Meeting of the American Society of Gene Therapy, which is being held at the San Diego Convention Center in San Diego, CA, ...
Other Contents
(Date:7/29/2014)... , July 29, 2014 Research and ... SaaS-based Business Intelligence (BI) Market 2014-2018" report to ... The term BI refers to applications ... to, or analyzing information about a company,s operations. BI ... affecting their business; for example, metrics on sales, production, ...
(Date:7/29/2014)... But on the remote UK overseas territory of Ascension ... is undergoing something of a renaissance. , Writing in ... the University of Exeter and Ascension Island Government Conservation ... at the remote South Atlantic outpost has increased by ... the 1970s. As many as 24,000 nests are now ...
(Date:7/29/2014)... University of Maryland Schools of Dentistry (UM SOD) ... they have received a five-year $10.7 million grant ... Infectious Diseases (NIAID) of the National Institutes of ... of sexually-transmitted diseases (STDs). The grant, which renews ... represents a new direction for the research by ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4
(Date:7/29/2014)... (PRWEB) July 29, 2014 Biocides are ... and control bacteria or fungi growth and to prevent ... within the material and its surface. It is used ... wood preservation, food and beverage, paints and coatings. It ... and sanitizers, as well as in industrial applications to ...
(Date:7/29/2014)... The U.S. should significantly reform the federal system ... ensure that the public,s $15 billion annual investment ... says a new report by the Institute of ... Medicare -- requires little accountability, allocates funds independent ... insufficient opportunities to train physicians in the health ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Frank Davis, ... powders can help parents add nutrition to their kids’ ... Bites – Key market drivers in kids’ foods market” ... is pleased to announce the interview Frank Davis had ... the Activz organic vegetable and fruit produce powders to ...
(Date:7/29/2014)... State College of Medicine, have jointly received nearly ... data research network., The Patient-Centered Outcomes Research Institute ... and Affordable Care Act, awarded the funds to ... Johns Hopkins University -- and each of their ... together to create a Clinical Data Research Network, ...
(Date:7/29/2014)... July 29, 2014 According to a ... the leading global authority in medical device market research, ... grow to over $8 billion by 2018. This ... in the transcatheter heart valve market, which is comprised ... the transcatheter mitral valve repair (TMVR) segments. , There ...
Breaking Medicine News(10 mins):Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 2Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 3Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 4Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 2Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 3Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 2Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 3Health News:New network unites university health care research 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 3
Other TagsOther Tags